DK

Dilip Kumar

Active Director Director DIN 08011563
DIN 08011563 First appointment Jan 2018 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2018
Shareholding value •••• Premium profile

About Dilip Kumar

Data last updated:

Dilip Kumar is a Director at Rgeno Pharmaceuticals Private Limited (since 2018). The company operates in Pharma. Rgeno Pharmaceuticals Private Limited reported revenue of ₹1.6 Lakh (FY 2024).

DIN 08011563
Primary Designation Director
Industry Pharma
First Appointment 18 Jan 2018
Oldest Company Age 8 yrs
Largest company Rgeno Pharmaceuticals Private Limited · ₹1.6 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director18 Jan 20182018₹1.6 Lakh (FY 2024)Active

Board colleagues of Dilip Kumar

NameDINCompanyDesignation
Deepak Kumar08011557Rgeno Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Rgeno Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Dilip Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dilip Kumar

Dilip Kumar currently holds 1 directorship: Rgeno Pharmaceuticals Private Limited (Director, since 18 Jan 2018, revenue ₹1.6 Lakh (FY 2024)).

Dilip Kumar was first appointed on 18 Jan 2018 as Director at Rgeno Pharmaceuticals Private Limited.

The current boards of Dilip Kumar's companies include Deepak Kumar (Rgeno Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available